Tranexamic Acid in Reducing Blood Loss in Patients With Pelvic Tumors Undergoing Hemipelvectomy Surgery

Running, not enrolling · Early Phase 1

Conditions studied: Pelvic Mass

In brief

This early phase I trial studies how well tranexamic acid works in reducing the loss of blood in patients with pelvic tumors undergoing hemipelvectomy surgery. Tranexamic acid decreases blood loss by stabilizing clots and preventing clot lysis in patients undergoing surgery.

Key facts

Study ID

NCT03128866

Run by

M.D. Anderson Cancer Center

People needed

80

Starts

2017-05-19

Expected to finish

2026-05-31

Last updated by the study team

2026-03-05

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Both pediatric and adult patients can be eligible to participate
• Cognitively impaired and non-English speakers can be eligible to participate.
• Both male and female patients must have a pelvic tumor and are scheduled to have surgery at University of Texas (UT) Monroe Dunaway (MD) Anderson Cancer center that require hemipelvectomy, resulting in pelvic ring disruption

You may not qualify if…

• Patient with a history of genetic prothrombotic state
• Patient with a history of thromboembolic disease to include pulmonary embolus or other extremity deep venous thrombosis
• Patients with thrombosis of the planned site of resection will not be excluded if the thrombus is caused directly by tumor burden or outflow obstruction
• Female patients will not be eligible for this study if she is either pregnant or nursing at the time of enrollment
• Patients will not be eligible if they have a history of color vision defects
• Patients will not be eligible if they have a history of retinal vein or artery occlusion
• Patients will not be eligible if they have a history of intracranial hemorrhage in past 6 months
• Patients will not be eligible if they have a history of hypersensitivity to tranexamic acid
• Patients will not be eligible if they present with moderate to severe decrease in creatinine clearance (estimated glomerular filtration rate [eGFR] < 45 mL/min/1.73m2)
• Patients will not be eligible if they present or have a history of seizure disorder

Where it is running

• M D Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.